Effects of high dose methylprednisolone pulse therapy on bone mass and biochemical markers of bone metabolism in patients with active rheumatoid arthritis: A 12-month randomized prospective controlled study

Journal of Rheumatology

Volumn 31, Issue 6, 2004, Pages 1083-1087

  Frediani, Bruno ^a,b   Falsetti, Paolo ^a   Bisogno, Stefania ^a   Baldi, Fabio ^a   Acciai, Caterina ^a   Filippou, Georgios ^a   Bacarelli, Maria Romana ^a   Filipponi, Paolo ^c   Galeazzi, Mauro ^b   Marcolongo, Roberto ^a  

^a Department of Rheumatology ^*  (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Bone mineral density; Bone turnover; Corticosteroid induced osteoporosis; Dual energy x ray absorptiometry; Glucocorticoid pulse therapy; Rheumatoid arthritis

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; BIOLOGICAL MARKER; CORTICOSTEROID; DEOXYPYRIDINOLINE; METHOTREXATE; METHYLPREDNISOLONE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE MINERAL; BONE TURNOVER; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG EFFECT; DRUG MEGADOSE; DRUG PULSE THERAPY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME BLOOD LEVEL; FEMALE; FEMUR NECK; HUMAN; INTERMETHOD COMPARISON; LOW DRUG DOSE; LUMBAR SPINE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; URINE LEVEL;

ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BONE DENSITY; DENSITOMETRY, X-RAY; FEMALE; FEMUR NECK; HUMANS; LUMBAR VERTEBRAE; METHYLPREDNISOLONE; MIDDLE AGED; PROSPECTIVE STUDIES; PULSE THERAPY, DRUG; TREATMENT OUTCOME;

EID: 2642535907     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Adachi JD, Olszynski WP, Hanley DA, et al. Management of corticosteroid-induced osteoporosis. Semin Arthritis Rheum 2000;29:228-51.
2. Reid IR. Glucocorticoid osteoporosis: mechanism and management. Eur J Endocrinol 1997;137:209-17.
3. Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 1995;54:49-52.
4. Adami S, Righetti D, Frigo A. L'osteoporosi cortisonica: Corticosteroid induced osteoporosis. Reumatismo 2000;52:77-85.
5. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. The effects of low-dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol 1995;22:1055-9.
6. Sinigaglia L, Nervetti A, Mela Q, et al. A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. J Rheumatol 2000;27:2582-9.
7. Van Staa TP, Leufkens HG, Abenhaim L, Zhang P, Cooper C. Use of oral corticosteroids and risk of fracture. J Bone Miner Res 2000;15:993-1000.
8. Verstraeten A, Dequeker J. Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids. Ann Rheum Dis 1986;45:852-7.
9. Reid IR. Steroid osteoporosis. Calcif Tissue Int 1989;45:63-7.
10. Hodgson S. Corticosteroid-induced osteoporosis. Endocrinol Metab Clin North Am 1990;19:95-111.
11. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998;102:274-82.
12. Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci 2002;966:73-81.
13. Heytman M, Ahern MJ, Smith MD, Roberts-Thomson PJ. The longterm effect of pulsed corticosteroids on the efficacy and toxicity of chrysotherapy in rheumatoid arthritis. J Rheumatol 1994;21:435-41.
14. Weusten BL, Jacobs JW, Bijlsma JW. Corticosteroid pulse therapy in active rheumatoid arthritis. Semin Arthritis Rheum 1993;23:183-92.
15. Chevalet P, Barrier JH, Pottier P, et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J Rheumatol 2000;27:1484-91.
16. Jacobs JWJ, Geenen R, Evers AWM, Van Jaarsveld CHM, Kraaimaat FW, Bijlsma JWJ. Short term effects of corticosteroid pulse treatment on disease activity and the wellbeing of patients with active rheumatoid arthritis. Ann Rheum Dis 2001;60:61-4.
17. Sato M, Takeda A, Honzu H, Saku N, Minato N, Kano S. Adult Still's disease with Sjogren's syndrome successfully treated with intravenous pulse methylprednisolone and oral cyclophosphamide. Intern Med 1993;32:730-2.
18. Job-Deslandre C, Menkes CJ. Administration of methylprednisolone pulse in chronic arthritis in children. Clin Exp Rheumatol 1991;9:15-8.
19. Webb J. Pulse steroid therapy in rheumatoid arthritis. Ann Rheum Dis 1988;47:879-80.
20. Baylis EM, Williams IA, English J, Marks V, Chakraborty J. High dose intravenous methylprednisolone pulse therapy in patients with rheumatoid disease. Plasma methylprednisolone levels and adrenal function. Eur J Clin Pharmacol 1982;21:385-8.
21. Miller JJ 3rd. Prolonged use of large intravenous steroid pulses in the rheumatic diseases of children. Pediatrics 1980;65:989-94.
22. Emkey RD, Lindsay R, Lyssy J, Weisberg JS, Dempster DW, Shen V. The systemic effect of intraarticular administration of corticosteroid on markers of bone formation and bone resorption in patients with rheumatoid arthritis. Arthritis Rheum 1996;39:277-82.
23. Lems WF, Jacobs JWG, Van Den Brink HR, Van Rijn HJM, Bijlsma JWJ. Transient decrease in osteocalcin and markers of type I collagen turnover during high-dose corticosteroid pulse therapy in rheumatoid arthritis. Br J Rheumatol 1993;32:787-9.
24. Lems WF, Gerris MI, Jacobs JWG, Van Vugt RM, Van Rjin HJM, Bijlsma JWJ. Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis. Ann Rheum Dis 1996;55:288-93.
25. Van der Veen MJ, Bijlsma JWJ. Effects of different regimes of corticosteroid treatment on calcium and bone metabolism in rheumatoid arthritis. Clin Rheumatol 1992;11:388-92.
26. Kollerup G, Hansen M, Hørslev-Petersen K. Urinary hydroxypyridinium cross-links of collagen in rheumatoid arthritis. Relation to disease activity and effects of methylprednisolone. Br J Rheumatol 1994;33:816-20.
27. Jacobs JWG, de Nijs RNJ, Lems WF, Bijlsma JWJ. Bone metabolism in rheumatoid arthritis. Clin Exp Rheumatol 2000;18:S5-S11.
28. Schwild SR, Goodman AD, Puzas JE, McDermott MP, Mattson DH. Sporadic corticosteroid pulses and osteoporosis in multiple sclerosis. Arch Neurol 1996;3:753-7.
29. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1998;31:315-24.
30. Manolagas SC, Weinstein RS. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 1999;14:1061-6.
31. Gluck OS, Murphy WA, Hahn TJ, Hahn B. Bone loss in adults receiving alternate day glucocorticoid therapy. A comparison with daily therapy. Arthritis Rheum 1981;24:892-8.
32. Sebaldt RJ. Pulse steroid therapy and the search for improved drug therapy of rheumatoid arthritis. J Rheumatol 1998;15:200-1.
33. Dessein PH, Shipton EA, Budd K. Oral low dose glucocorticosteroids as compared with intravenous methylprednisolone pulses in the treatment of rheumatoid arthritis. Rheumatology Oxford 1999;38:1304-5.
34. Buttgereit F, Wehling M, Burmester GR. A new hypothesis of modular glucocorticoid actions. Arthritis Rheum 1998;41:761-7.
35. Buttgereit F, Brand MD, Burmester JR. Equivalent doses and relative drug potencies for non-genomic glucocorticoid effects: a novel glucocorticoid hierarchy. Biochem Pharmacol 1999;58:363-8.